Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.65 |
| ▸ | JAK3 | P52333 | 9/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271514 | 0.85 | JAK2 (0.62) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL2634396 | 0.84 | JAK2 (0.70) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL3260453 | 0.82 | JAK2 (0.72) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL15796859 | 0.82 | JAK2 (0.72) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL18367046 | 0.82 | JAK2 (0.77) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL3260096 | 0.81 | JAK2 (0.70) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL2251442 | 0.81 | JAK2 (0.70) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL2254342 | 0.81 | JAK2 (0.72) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL13535736 | 0.80 | JAK2 (0.60) | JAK2JAK3JAK1NUDT1PTK2 | |
| SCHEMBL2640579 | 0.80 | JAK2 (0.75) | JAK2JAK3JAK1NUDT1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | JAK2 3153/4885JAK3 4312/4885JAK1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.